Related Experiment Videos
The chronic efficacy of midazolam
J Lamphere1, T Roehrs, G Vogel
1Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, Michigan 48202.
International Clinical Psychopharmacology
|January 1, 1990
Summary
Midazolam effectively treats insomnia by reducing sleep latency and increasing total sleep time over five weeks. This medication demonstrated no rebound effects or residual daytime issues in chronic insomnia patients.
Area of Science:
- Pharmacology
- Sleep Medicine
- Clinical Trials
Background:
- Insomnia, particularly sleep onset insomnia, is a prevalent sleep disorder.
- Polysomnography is a key diagnostic tool for verifying sleep disorders.
- Chronic treatment efficacy for insomnia medications requires thorough investigation.
Purpose of the Study:
- To evaluate the chronic efficacy of midazolam 15.0 mg in patients with sleep latency insomnia.
- To assess the long-term effects of nightly midazolam administration over a 5-week period.
- To determine the safety profile, including rebound insomnia and residual daytime effects.
Main Methods:
- A 5-week nightly administration study design was employed.
- Midazolam 15.0 mg was administered for 35 nights, with placebo on the initial 8 and final 2 nights.
- Polysomnography was used for subject screening and verification of sleep latency insomnia.
Main Results:
- Midazolam significantly reduced sleep latency parameters throughout the 5-week treatment period.
- Total sleep time was significantly increased with nightly midazolam administration.
- No instances of within-night rebound insomnia, residual daytime effects, or discontinuation rebound were observed.
Conclusions:
- Midazolam 15.0 mg demonstrates chronic efficacy in improving sleep latency and total sleep time.
- The medication appears safe for long-term use, with no significant adverse effects upon discontinuation.
- Midazolam is a viable therapeutic option for managing chronic sleep latency insomnia.